A Review of the Use of Secukinumab for Psoriatic Arthritis

@article{Patel2017ARO,
  title={A Review of the Use of Secukinumab for Psoriatic Arthritis},
  author={N. Patel and N. Vera and E. Shealy and M. Wetzel and S. Feldman},
  journal={Rheumatology and Therapy},
  year={2017},
  volume={4},
  pages={233 - 246}
}
Psoriatic arthritis (PsA) is a chronic, seronegative spondyloarthropathy associated with psoriasis (PsO). Treatment options range from non-pharmacologic measures to NSAIDS, DMARDs, and biologics, depending on patient presentation. Secukinumab (Cosentyx©) is a new biologic treatment option that was approved for use in treating adult patients with PsA in October 2016. Our paper explores the clinical trial evidence available for secukinumab to examine its safety and efficacy as a therapeutic agent… Expand
11 Citations
The role of secukinumab in the treatment of psoriatic arthritis and ankylosing spondylitis
  • 11
  • PDF
Treatment of psoriatic arthritis with secukinumab: a case series
  • 3
Th17 cell responses in spondyloarthritis.
  • 5
Immunologic Adverse Effects of Biologics for the Treatment of Atopy
  • 2
Role of the IL-23/IL-17 Pathway in Rheumatic Diseases: An Overview
...
1
2
...

References

SHOWING 1-10 OF 34 REFERENCES
Secukinumab: A New Treatment Option for Psoriatic Arthritis
  • 39
  • Highly Influential
  • PDF
Management of psoriatic arthritis in 2016: a comparison of EULAR and GRAPPA recommendations
  • 67
  • Highly Influential
  • PDF
Secukinumab for rheumatology: development and its potential place in therapy
  • 21
  • PDF
Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis.
  • 466
  • Highly Influential
  • PDF
European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update
  • 685
  • Highly Influential
  • PDF
Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis.
  • 519
  • PDF
New GRAPPA recommendations for the management of psoriasis and psoriatic arthritis: process, challenges and implementation
  • 33
...
1
2
3
4
...